Takeaway

• In patients with adult-onset neuroblastoma (AON), the use of ALK inhibitors (ALKi) can be a well-tolerated option for treatment, improving time to progression.
• Treatment with serial ALKi is not precluded in case of the development of resistance to one agent.

Why this matters

• AON is rare, challenging to treat disease,...